SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Down 5.5% – Should You Sell?

SOPHiA GENETICS SA (NASDAQ:SOPH) was down 5.5% on Tuesday. The company traded as low as $7.80 and last traded at $7.75. Approximately 414,599 shares were traded during trading, an increase of 36% from the average daily volume of 304,445 shares. The stock had previously closed at $8.20.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Insiders retained substantial positions after the transactions, suggesting the sales do not represent a broad exit from the company. SOPHiA GENETICS also has a consensus analyst price target of approximately $10.00, above recent trading levels.
• Neutral Sentiment: The reported sales were executed under pre-arranged Rule 10b5-1 trading plans to cover tax withholding after equity awards vested. This reduces their value as a discretionary bearish signal, but the transactions can still create near-term selling pressure. SOPHiA GENETICS insider selling report
• Negative Sentiment: Several senior executives and directors sold shares on October 5 at prices of roughly $8.04 to $8.13. Sellers included CEO Ross Muken, Chairman Jurgi Camblong, CFO George Cardoza, CTO Abhimanyu Verma and other insiders. The group sold approximately $669,000 worth of stock, which may be contributing to investor caution.
• Negative Sentiment: The selling comes as SOPH remains unprofitable. The company’s latest quarterly loss missed analyst expectations, and analysts anticipate a full-year loss of approximately $0.77 per share. The stock is also trading below its 50-day moving average, reinforcing weaker near-term momentum.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. BTIG Research boosted their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright lifted their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. Finally, Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research note on Tuesday, July 21st. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $10.00.

SOPHiA GENETICS Stock Performance

The stock has a market capitalization of $599.81 million, a P/E ratio of -6.22 and a beta of 0.95. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. The business has a fifty day moving average price of $7.85 and a 200-day moving average price of $6.14.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The business had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Insider Transactions at SOPHiA GENETICS

In other news, CTO Abhimanyu Verma sold 5,284 shares of SOPHiA GENETICS stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total value of $42,906.08. Following the completion of the sale, the chief technology officer directly owned 166,887 shares in the company, valued at $1,355,122.44. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Well Van sold 6,168 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $8.12, for a total transaction of $50,084.16. Following the transaction, the insider directly owned 332,716 shares of the company’s stock, valued at $2,701,653.92. The trade was a 1.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 300,043 shares of company stock valued at $2,229,096. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently modified their holdings of the company. Silverberg Bernstein Capital Management LLC boosted its position in SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares in the last quarter. Principal Financial Group Inc. increased its stake in SOPHiA GENETICS by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after purchasing an additional 9,800 shares in the last quarter. First Dallas Securities Inc. acquired a new position in shares of SOPHiA GENETICS in the 1st quarter valued at $50,000. 1492 Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 8.4% in the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after purchasing an additional 17,406 shares during the period. Finally, Royal Bank of Canada raised its position in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after buying an additional 18,781 shares during the last quarter. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.